clinical outcomes for patients with myelofibrosis after transition from ruxolitinib to momelotinib
Published 1 month ago • 333 plays • Length 1:01Download video MP4
Download video MP3
Similar videos
-
2:36
phase ii study of pre-, during-, and post-transplant ruxolitinib for patients with myelofibrosis
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
2:10
phase i study of ruxolitinib in combination with abemaciclib in patients with myelofibrosis
-
5:12
ongoing clinical trials of ruxolitinib-based combinations in myelofibrosis
-
3:20
safety and anemia outcomes with momelotinib vs pacritinib in patients with myelofibrosis
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
2:05
investigating the efficacy of tp-3654 in patients with myelofibrosis: results from phase i study
-
20:01
primary myelofibrosis - overview (presentation, pathophysiology, investigation, treatment)
-
30:42
evolving myelofibrosis treatment options: what you should know
-
7:18
how might luspatercept benefit patients with myelofibrosis?
-
2:00
the development of anti-fibrotic agents for treating myelofibrosis
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
4:25
update on momelotinib for myelofibrosis
-
2:16
long-term safety of momelotinib for myelofibrosis
-
2:02
analyses from comfort trials of ruxolitinib for myelofibrosis
-
1:15
ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis
-
1:45
momelotinib vs soc in patients with mf and anemia: an analysis from the simplify-2 trial
-
2:10
management of ruxolitinib failure in myelofibrosis
-
1:53
parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
-
2:39
a phase ii trial of ruxolitinib and azacitidine combination therapy in patients with myelofibrosis
-
1:20
the impact of early ruxolitinib treatment on os in the comfort-i and comfort-ii studies